Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

COX-2 gene expression in colon cancer tissue related to regulating factors and promoter methylation status

  • Annika Gustafsson Asting1,
  • Helena Carén2,
  • Marianne Andersson1,
  • Christina Lönnroth1,
  • Kristina Lagerstedt1 and
  • Kent Lundholm1Email author
BMC Cancer201111:238

DOI: 10.1186/1471-2407-11-238

Received: 2 February 2011

Accepted: 13 June 2011

Published: 13 June 2011

Abstract

Background

Increased cyclooxygenase activity promotes progression of colorectal cancer, but the mechanisms behind COX-2 induction remain elusive. This study was therefore aimed to define external cell signaling and transcription factors relating to high COX-2 expression in colon cancer tissue.

Method

Tumor and normal colon tissue were collected at primary curative operation in 48 unselected patients. COX-2 expression in tumor and normal colon tissue was quantified including microarray analyses on tumor mRNA accounting for high and low tumor COX-2 expression. Cross hybridization was performed between tumor and normal colon tissue. Methylation status of up-stream COX-2 promoter region was evaluated.

Results

Tumors with high COX-2 expression displayed large differences in gene expression compared to normal colon. Numerous genes with altered expression appeared in tumors of high COX-2 expression compared to tumors of low COX-2. COX-2 expression in normal colon was increased in patients with tumors of high COX-2 compared to normal colon from patients with tumors of low COX-2. IL1β, IL6 and iNOS transcripts were up-regulated among external cell signaling factors; nine transcription factors (ATF3, C/EBP, c-Fos, Fos-B, JDP2, JunB, c-Maf, NF-κB, TCF4) showed increased expression and 5 (AP-2, CBP, Elk-1, p53, PEA3) were decreased in tumors with high COX-2. The promoter region of COX-2 gene did not show consistent methylation in tumor or normal colon tissue.

Conclusions

Transcription and external cell signaling factors are altered as covariates to COX-2 expression in colon cancer tissue, but DNA methylation of the COX-2 promoter region was not a significant factor behind COX-2 expression in tumor and normal colon tissue.

Background

Colorectal cancer is common in Western countries with unanimous findings that prostaglandins are important for both carcinogenesis and progression [13]. It has been repeatedly observed that Cyclooxygenase-1/-2 inhibition attenuates appearance of epithelial cancer in experimental models and in part also in patients. Both primary and secondary prevention with cyclooxygenase (COX) inhibitors demonstrate and confirm decreased incidence of colorectal carcinoma in both retrospective and randomized patient cohorts [47]. Thus, a large number of observations emphasize that induced prostaglandin production, particularly PGE2, is involved in cell signaling through prostanoid receptors, where our own observations suggested subtype EP2 receptor expression in colon cancer tissue to predict reduced survival [2]. An important issue behind the appearance and progression of colorectal cancer seems to be increased production of PGE2 secondary to COX-2 induction in both transformed epithelial cells and host stroma [2, 4, 811]. Mechanisms behind COX-2 gene induction in colorectal cancer disease remain elusive, although a lot of information is available on the regulation of COX-2 gene expression [12, 13]. Most such information has, however, been obtained in isolated cell culture experiments with obvious limitations compared to the in vivo situation based on uninterrupted host and tumor cell signaling. Therefore, the aim of the present study was to relate well-recognized external cell- and transcription factor expression to elevated tumor COX-2 expression in colorectal cancer tissue at primary operations aimed at cure.

Methods

Patients

Tumor and colon tissue samples were collected from 48 unselected patients at primary operation for colorectal carcinoma between 2001 to 2004 in Uddevalla county of Sweden. All patients underwent surgery as the only curative treatment and none received neoadjuvant radio-chemotherapy, according to individual decisions and institutional indications. Normal colon tissue was collected as a minimum of 10 cm away from the macroscopically seen tumor tissue. The group of patients consisted of 54% males and 46% females with a mean age of 72.5 years (range 40 to 91 years) at surgery. Mean survival time was 27.3 ± 4.2 months (range 0 to 73 months) following surgery according to a recent update of survival (Dec 2008), where 21 patients were still alive. Tumors were histologically classified as Dukes A (8), Dukes B (19), Dukes C (11) and Dukes D (10). PCR analysis was performed to quantify COX-2 mRNA expression [2]. Mean COX-2 expression in tumor tissue for the entire group was 6.27 ± 0.60 mol/mol GAPDH (range 0.11 to 24.67) (n = 48) and 14.6 ± 1.7 (range 1.7 to 38.08) (n = 29) in normal colon tissue. Patients used in subsequent experiments were selected according to COX-2 expression in tumors; one group of 10 patients with highest and one group of 10 patients with lowest COX-2 expression (Figure 1, Table 1).
https://static-content.springer.com/image/art%3A10.1186%2F1471-2407-11-238/MediaObjects/12885_2011_Article_2725_Fig1_HTML.jpg
Figure 1

Distribution of COX-2 among patients (n = 48). COX-2 expressions of tumors used in this study were distributed at the top and bottom quartile.

Table 1

Classification of patients with high or low COX-2 expression in tumor tissue

 

COX-2 expression in tumor tissue

 

High (10)

Low (10)

COX-2 T

12.5 ± 1.5

2.6 ± 0.4

(mol/mol GAPDH) NM

5.06 ± 3.0

12.3 ± 4.0

Dukes1

3 A, 6 B, 1 D

3 B, 5 C, 2 D

Age at surgery

71 ± 2.5

73 ± 3.4

Gender

6 M, 4 F

4 M, 6 F

Postoperative survival (months)

23 ± 5.8

29 ± 8.0

Right/left colon

4/6

4/6

Mean ± SEM

T = tumor tissue

NM = Normal colon tissue

1Approx. TNM; A = T1, N0, M0; B = T2/T3, N0, M0; C = T2/T3/T4, N1/N2, M0; D = T2/T3/T4, N1/N2, M1

RNA and DNA extraction

Tumor and normal colon tissue samples were collected down to the serosa layer during surgery and kept fresh frozen in liquid nitrogen and stored in -80°C until analysis. Certified pathologists staged all tumors. Tumor samples were secured by the surgeon in charge and contained around 55-75% tumor cells according to random visual inspection. RNA extraction and cDNA synthesis were performed as described [2]. A quality check of RNA in all samples was done in Bioanalyzer 2100 with limit RIN 6.0 for further analysis (Agilent). DNA was extracted with QIAamp® DNA Mini Kit (Qiagen) according to instructions. RNase A solution (Promega) was used as extra step in DNA purification. Concentration of RNA and DNA was determined in NanoDrop® ND-1000 Spectrophotometer (NanoDrop Technologies).

Gene expression analysis

Microarray analysis was performed on pooled tumor mRNA from 9 out of 10 patients with high COX-2 mRNA expression versus 9 out of 10 patients with low COX-2 mRNA expression. The two patients were excluded due to low RIN indicating poor RNA quality. 500 ng of mRNA from tumors with high COX-2 patients was labeled with Cy-3-dCTP (Amersham BioSciences) in a cDNA synthesis reaction with Agilent Flourescent Direct Label. Tumor samples with low COX-2 expression (500 ng) were labeled with Cy-5-dCTP. Pooled tumor cDNA from patients with high COX-2 versus pooled DNA from patients with low COX-2 expression were then hybridized on whole human oligo genome microarrays (4 × 44K expression arrays, Agilent) during 18 hrs followed by post-hybridization washes according to in situ instructions (Hybridization Kit Plus, Agilent). Microarrays were quantified on Agilent G2565 AA microarray scanner and data were pre-processed in Feature Extraction 9.1 software program (Agilent). The same procedures were performed with normal colon mucosa tissue from all patients with only 4 patients per pool due to poor RNA quality. One hybridization with high COX-2 tumor expression versus corresponding normal colon mucosa tissue was also performed. Four technical replicates of all tumor tissue analyses and two technical replicates of normal colon tissue and tumor versus normal colon tissue analyses were performed. Dye-normalized, outlier- and background subtracted values were analyzed in GeneSpring GX 10 software program (Agilent) according to standard procedures. A quality control was performed with QC metrics. Analysis used were filter on flags (present or marginal) were 27194 probes (out of 41078) passed in 2 out of 4 technical replicates with tumor tissue. In normal tissue 25735 probes passed and in tumor vs normal tissue 27919 probes passed filter on flags for further analysis with t-test (p < 0.05). Fold change 1.5 of log2 transformed ratios was considered a statistically significant change in gene expression. Significant pathway analysis with entity list FC 1.5 was used to define significantly altered pathways. PCR analyses were performed at Tataa Biocenter (Gothenburg, Sweden) in a LightCycler 480 Probe Master (Roche). PCR assays (AKT1 HS00178289_m1, IL1B HS01555410_m1, IL6 HS00985639_m1, TRA@ HS 00612292_m1, CARD11 HS01060626_m1, Applied Biosystems) were tested and validated for efficiency and specificity. All samples were run in duplicate and negative controls were negative. Results were related to assay efficiency and GAPDH (GAPDH assay from Tataa Biocenter's Reference Gene Panel Human) and calculated according to comparative Ct method.

DNA methylation analysis with bisulfite sequencing

Methylation analysis was performed with tag-modified bisulfite genomic sequencing [14]. EpiTect® Bisulfite kit (Qiagen) was used for bisulphite modification of 1 μg tumor and normal colon tissue DNA from each patient (n = 20) according to instructions. Modified DNA samples were amplified with two different sets of primers (Table 2) directed towards two areas of the COX-2 promoter region using touchdown PCR (1 × Reaction Buffer, 0.5 mM dNTPs, 2.0 mM MgCl2, 0.4 μM forward and reverse primers resp., and 1 unit HotStart Taq (Qiagen). Primer pair 1 was taken from Hur et al. and primer pair 2 was designed with BiSearch [15, 16]. PCR reactions were denatured at 95°C for 10 min, then 20 cycles of 95°C 45 s, 60°C/65°C annealing temperature with a decrease of half a degree per cycle for 45 s, 68°C 60 s followed by 15-20 cycles of 95°C 45 s, 50°C/55°C 45 s and 68°C 60 s ended with a 7 min extension at 68°C. EpiTect® PCR Controls (Qiagen) was used to ensure that the reaction worked properly; one methylated control sample, one unmethylated control and a 50/50 mixture of methylated and unmethylated controls were included in each PCR to ensure that methylated and unmethylated template were both equally amplified. The specificity of PCR products was inspected by use of 2100 Bioanalyzer according to protocol for DNA 1000 (Agilent). PCR products were then purified using Agencourt AMPure magnetic beads (Agencourt Bioscience Corporation) using the Biomek NX pipetting robot (Beckman Coulter) and eluted in distilled water. Sequence PCR was performed using forward or reverse primer with the ABI Prism BigDye™ cycle sequencing Ready Reaction Kit v1.1 (Applied Biosystems). Sequence PCR was run in 10 μl reactions under following conditions: 96°C 1 min, followed by 25 cycles of 96°C 10 s and 50°C 4 min. Sequencing products were purified using CleanSeq magnetic beads (Agencourt) using the Biomek NX and re-suspended in 10 μl of High Dye formamide (Applied Biosystems). The sequencing products were separated with gel electrophoresis on a 3730 DNA analyser (Applied Biosystems) and the output data were viewed and analysed using Sequence Analysis v5.2 (Applied Biosystems) and BiqAnalyzer [17].
Table 2

Primers used for methylation analysis

 

Tag

Primer Sequence (5'-3')

Bp

1

FP1692

CCACTCACTCACCCACCCGAAGAAGAAAAGATATTTGG

448

1

RP2104

GGGTGGGAGGTGGGAGGGATAAACTTTACTATCTAAAA

 

2

B1(1595)

CCACTCACTCACCCACCCTTGGAGAGGAAGTTAAGTGTTT

223

2

b1(1782)

GGGTGGGAGGTGGGAGGGATCCCCACTCTCCTATCTAAT

 

Statistics

Results are presented as mean ± SEM. Statistical analyses were performed by ANOVA and p < 0.05 was regarded significant in two-tailed tests. This study was approved by the board of Ethics at University of Gothenburg (NCT00473980). Accordingly, all patients participated with informed consent.

Results

COX-2 expression

Large difference in gene expression was observed when comparing tumor tissue with high COX-2 expression to normal colon mucosa tissue from the same patients (2557↑, 3182↓) (Table 3). A large number of genes with altered expression appeared also in colon cancer tissue of tumors with high COX-2 expression when compared to tumors with low COX-2 expression (3086↑, 3031↓) (Table 4). Expression of COX-2 in normal colon mucosa tissue was significantly increased in patients with tumors of high COX-2 expression compared with mucosa from patients with low COX-2 expression in tumors (776↑, 804↓). Highly expressed genes in tumor tissue with high COX-2 expression were associated to cell motility, cell structure, muscle proteins, and energy homeostasis while down-regulated genes in such tumors seemed to be related to tumor antigens as Melanoma antigen and Chondrosarcoma ass. Gene, etc (Table 4). Several factors of immune response as serpin peptidase inhibitor and inducible metric oxide synthase 2 with antitumoral activities were either up- or down-regulated in normal colon tissue from patients with tumors of high COX-2 expression (Table 5). Patients with tumors with high COX-2 expression did not in the present material display significantly reduced survival compared to patients with tumors with low COX-2 expression (Table 1). However, COX-2 expression predicted survival at borderline significance in a larger patient material [2].
Table 3

Genes listed according to the magnitude of most altered expression between tumor tissue and normal mucosa from the same patients with tumors of high intrinsic COX-2 expression

Gene

↑/↓

FC

Function

Gene Symbol (GeneID)

Matrix metallopeptidase 7

110

Breakdown of extracellular matrix, metastasis

MMP7 (4316)

Keratin 23

77

Structural integrity of epithelial cells

KRT23 (25984)

Myosin

63

Muscle, heavy polypeptide 2

MYH2 (4620)

Claudin 1

38

Integral membrane protein, component of tight junction strands

CLDN1 (9076)

Actin α1, skeletal

36

Cell motility, structure and integrity

ACTA1 (58)

Forkhead box Q1

34

Transcription factor (i.e. TGF-beta2)

FOXQ1 (94234)

Proprotein convertase subtilisin/kexin type 1

22

Regulating insulin biosynthesis, obesity, activate precursor protein, associated with carcinoid tumors

PCSK1 (5122)

Sarcolipin

25

Regulates several sarcoplasmic reticulum Ca(2+)-ATPases

SLN (6588)

Matrix metallopeptidase 1

14

Breakdown of extracellular matrix, metastasis

MMP1 (4312)

Myosin, cardiac, beta

25

Heavy chain, also expressed in skeletal muscle tissues rich in slow-twitch type I muscle fibers

MYH7 (4625)

Hydroxy-δ-5-steroid dehydrogenase

79

Biosynthesis of steroid hormones, polymorphisms related to prostate cancer

HSD3B2 (3284)

Hydroxy-δ-5-steroid dehydrogenase

30

Biosynthesis of steroid hormones, diagnostic trophoblastic marker

HSD3B1 (3283)

similar to 3 β-hydroxysteroid dehydrogenase

28

Pseudogene

LOC391081 (391081)

-

24

unknown

CR627415

Butyrylcholinesterase

21

Homozygoutics sustain prolonged apnea after administration of the muscle relaxant suxamethonium

BCHE (590)

Neuronal pentraxin

19

Excitatory synapse remodelling, mediate neuronal death induced by reduction in neuronal activity in mature neurons

NPTX1 (4884)

Dipeptidyl-peptidase 6

18

Binds and alters specific voltage-gated potassium channels expression and biophysical properties

DPP6 (1804)

ATP-binding cassette, sub-family G

17

Breast cancer resistance protein, xenobiotic transporter may play a major role in multi-drug resistance

ABCG2 (9429)

Insulin like-5

17

Relaxin/Insulin family, ligand for GPCR142

INSL5 (10022)

Regenerating islet-derived 1 β

16

Highly similar to REG1A protein (islet cell regeneration and diabetogenesis)

REG1B (5968)

increased expression

decreased expression

Table 4

Genes listed according to the magnitude of most altered expression in tumor tissue of high intrinsic COX-2 expression

Gene

↑/↓

FC

Function

Gene Symbol (GeneID)

Unknown

156

unknown

W60781

Myosin

107

Muscle, heavy polypeptide 2

MYH2 (4620)

Desmin

49

Muscle filament

DES (1674)

Creatine kinase

46

Muscle, energy homeostasis, serum marker for myocardial infarction

CKM (1158)

Troponin T type 3

41

Skeletal

TNNT3 (7140)

Actin α, cardiac

37

Muscle, contractile, cell motility

ACTC1 (70)

Actin α1, skeletal

35

Cell motility, structure and integrity

ACTA1 (58)

Synaptopodin 2

28

Cell-shape regulation, homolog with Myopodin (a tumor suppressor; inhibits growth and metastasis)

SYNPO2 (171024)

Nebulin

25

Cytoskeletal matrix

NEB (4703)

Calponin

23

Differentiation marker, reduced in tumor vessels associated with tumor progression

CNN1 (1264)

Growth diff. factor 10

28

Regulation of cell growth and differentiation

GDF10 (2662)

Unc-13 homolog A

19

diacylglycerol and phorbol ester receptors, essential role in synaptic vesicle priming

UNC13A (23025)

LOC553137

16

miscRNA, unknown function

LOC553137 (553137)

Melanoma antigen family B, 2

14

Tumor-associated antigen, expressed only in testis and tumors, regulated by demethylation

MAGEB2 (4113)

Chondrosarcoma associated gene 1

13

Tumor antigen, expressed in testis and in chondrosarcomas

CSAG1 (158511)

Folate receptor 1

13

Involvement in cancer prognosis

FOLR1 (2348)

Renin

13

Blood pressure and electrolyte balance

REN (5972)

Small proline-rich protein 3

12

Epithelial homeostatis, aberrant expression contribute to tumorigenesis of esophageal squamous cell carcinoma

SPRR3 (6707)

Heat shock 27kDa protein 3

12

Muscle

HSPB3 (8988)

Chromogranin B

11

Precursor for biological active peptides, involved early in breast cancer

CHGB (1114)

increased expression

decreased expression

Table 5

Genes listed according to the magnitude of most altered expression in normal mucosa from patients with tumors of high intrinsic COX-2 expression

Gene

↑/↓

FC

Function

Gene Symbol (GeneID)

Pancreatic derived factor (PANDER)

79

Cytokine, induces apoptosis of alpha and beta cells, implicated in diabetes

FAM3B (54097)

Regenerating islet-derived 1 α

40

Secreted by the exocrine pancreas, associated with islet cell regeneration and diabetogenesis

REG1A (5967)

Ribosomal protein S4, Y-linked 2

40

Translation

RPS4Y2 (140032)

Serpin peptidase inhibitor, ovalbumin

35

Cytoprotective, cell survival factor, monocyte regulation, potential cancer marker (elevated in plasma)

SERPINB2 (5055)

Nitric oxide synthase 2, inducible

19

reactive free radical, biologic mediator in several processes, incl. neurotransmission, antimicrobial and antitumoral activities

NOS2A (4843)

Pentraxin-related gene

16

Immune response, inflammation, rapidly induced by IL-1β

PTX3 (5806)

Regenerating islet-derived 1 β

16

highly similar to REG1A protein

REG1B (5968)

Hydroxy-delta-5-steroid dehydrogenase

10

Biosynthesis of steroid hormones, polymorphisms related to prostate cancer

HSD3B2 (3284)

Hydroxy-delta-5-steroid dehydrogenase

10

Biosynthesis of steroid hormones, diagnostic trophoblastic marker

HSD3B1 (3283)

ADAM metallopeptidase

10

cleavage of proteoglycans, control of organ shape during development, and inhibition of angiogenesis

ADAMTS9 (56999)

Unknown

15

unknown

ENST00000343

6-phosphofructo-2-kinase

13

Produce fructose 2,6-P(2), involved in Warburg effect

PFKFB3 (5209)

hemoglobin, γ A

8

Normally expressed in the fetal liver, spleen and bone marrow

HBG1 (3047)

matrix metallopeptidase 7

8

Breakdown of extracellular matrix, metastasis

MMP7 (4316)

Fc receptor-like 4

7

Immune regulation

FCRL4 (83417)

Chemokine receptor 5

6

B cell migration and localization

BLR1 (643)

Fibroblast growth factor 5

6

Mitogenic and cell survival activities, involved in a variety of biological processes, incl. cell growth, morphogenesis, tissue repair, tumor growth and invasion, oncogene

FGF5 (2250)

Family with sequence similarity 129, member C

6

B-cell novel protein, BCNP1 completely unknown protein with 3 predicted transmembrane domains

FAM129C (199786)

selectin L

6

Leukocyte-endothelial cell interactions

SELL (6402)

Zinc finger protein

5

DNA binding

ZNF683 (257101)

increased expression

decreased expression

Transcription factors

A large number of transcription factors with reported importance for regulation of the COX-2 gene in human cells were evaluated and are listed in Table 6. Eight of these transcription factors showed increased expression, while 5 transcription factors were down-regulated in tumors with high COX-2 expression.
Table 6

Significant alterations in expression of previously reported important transcription factors in tumors of high intrinsic COX-2 expression

Gene

Product

FC 1.5

FC 2.0

FC 3.0

Referencea

TFAP2C

AP-2γ

-

-

[12]

TFAP2E

AP-2ε

-

-

-

[12]

ATF1

ATF1

-

-

-

[13]

ATF2

ATF2/CREB2

-

-

-

[13]

ATF3

ATF3/AP1

-

-

[13]

BATF

B-ATF

-

-

-

[13]

CREBBP

CBP/p300 co-activator

-

-

-

[12]

CDX2

CDX2

-

-

[29]

CEBPA

C/EBP-α

-

-

-

[13]

CEBPB

C/EBP-β

-

-

-

[13]

CEBPD

C/EBP-δ

-

[13]

CREB5

CRE-BPA

-

-

-

[13]

CREB1

CREB

-

-

-

[13]

ELK1

Elk-1

-

-

[13]

FOS

c-Fos/AP1

-

-

[12]

FOSB

Fos-B/AP1

[12]

FOSL1

Fra-1/AP1

-

-

-

[12]

FOSL2

Fra-2/AP1

-

-

-

[12]

DNAJC12

JDP1

-

-

-

[12]

JDP2

JDP2

-

-

[12]

JUN

Jun/AP1

-

-

-

[12]

JUNB

JunB/AP1

-

-

-

[12]

JUND

JunD/AP1

-

-

[12]

MAF

c-Maf/AP1

-

[12]

NFATC1

NFATc1/NFAT2

-

-

-

[12]

NFATC4

NFAT3

-

-

-

[12]

NFATC3

NFAT4

-

-

-

[12]

NFAT5

NFAT5

-

-

-

[12]

NFKB1

NF-κB, p105/p50

-

-

-

[12, 13]

NFKB2

NF-κB, p100

-

-

-

[12, 13]

RELA

NF-κB, RelA (p65)

-

-

-

[12, 13]

RELB

NF-κB, RelB

-

-

-

[12, 13]

REL

NF-κB, c-Rel

-

-

-

[12, 13]

NFKBIA

NF-κB, IκBα

-

[12, 13]

NFKBIB

NF-κB, IκBβ

-

-

-

[12, 13]

NFKBIE

NF-κB, IκBε

-

-

-

[12, 13]

CHUK

NF-κB, IKK-α

-

-

-

[12, 13]

IKBKB

NF-κB, IKK-β

-

-

-

[12, 13]

IKBKG

NF-κB, IKK-γ

-

-

-

[12, 13]

TP53

p53

-

[30]

ETV4

PEA3

-

-

[13]

PPARA

PPARα

-

-

-

[12]

PPARD

PPARβ/δ

-

-

-

[12]

PPARG

PPARγ

-

-

-

[12]

SP1

SP-1

-

-

-

[12]

TBP

TATA-binding protein

-

-

-

[12]

TCF4

TCF4

-

[13]

AP-2α, AP-2β, AP-2δ, NFAT1 and Retinoic acid receptor were also tested, but no expression were found.

increased expression; decreased expression; FC is log2 fold changes

a published report with emphasis on transcription factor in regulation of COX-2 gene.

External factors

Genes with reported functions in external cell signaling indicated 6 genes with increased expression, while no gene indicated down-regulation related to high COX-2 expression in tumor tissue (Table 7). Table 8 describes genes with significantly altered expression of transcription factors and external cell signaling factors in normal mucosa from patients with tumors of increased COX-2 expression. IL1-β, IL6, and iNOS were up-regulated, probably inducing a variety of transcription factors.
Table 7

Significant alterations in expression of previously reported important external cell signaling factors and enzymes in tumors of high intrinsic COX-2 expression

Gene

Product

FC 1.5

FC 2.0

FC 3.0

Referencea

DNMT1

DNA MTase 1

-

-

-

[26]

DNMT3A

DNA MTase 3A

-

[26]

DNMT3B

DNA MTase 3B

-

-

-

[26]

MDM2

hdm2

-

-

-

[30]

HPGD

HPGD

-

-

-

[1]

HNRPD

HuR

-

-

-

[31]

IL1B

IL1b

-

[32, 33]

IL6

IL6

[34]

IL6R

IL6 receptor

-

-

[34]

NOS2A

iNOS

-

-

-

[13]

MAPK14

p38 MAPK

-

-

-

[35]

PTGES

mPGES-1

-

-

-

[1]

PRKCB1

Protein kinas Cβ1

[12]

RALA

Ras family (oncogene)

-

-

-

[12]

RASA4

Ras p21 protein activator

-

-

-

[12]

RASSF1

Ras ass. (tumor supr.)

-

-

-

[12]

RIN2

Ras and Rab interact. 2

-

-

-

[12]

TINP1

TGF-β

-

-

-

[13]

TNF

TNF-α

-

-

[13]

increased expression

decreased expression

FC is log2 fold change

a published report with emphasis on the current factors

Table 8

Significant alterations in expression of transcription factors and cell signaling factors in normal colon mucosa from patients with tumors of high intrinsic COX-2 expression

Gene

Product

FC 1.5

FC 2.0

FC 3.0

PTGS2

COX-2

Transcription

    

ATF3

ATF3/AP1

-

-

CEBPD

C/EBP-δ

-

CREB1

CREB

-

-

FOSB

Fos-B/AP1

-

DNAJC12

JDP1

-

-

NFATC1

NFATc1/NFAT2

-

-

PPARG

PPARγ

-

-

BATF

B-ATF

-

-

External cell factors

   

IL1B

IL1b

IL6

IL6

NOS2A

iNOS

All factors listed in Table 6 and 7 were evaluated.

Pathway analysis

Significantly altered metabolic and signaling pathways (FC 1.5) in tumors with high COX-2 expression were mainly related to immunity according to algorithm analyses (GeneSpring GX 10, Agilent). Five genes that were significantly changed in arrays (AKT1, CARD11, IL1B, IL6, and TRA@) and involved in significantly changed pathways according to the algorithm analyses (TCR, BCR, IL1, and IL6) were tested individually (Table 9). All results from individual PCR analyses agreed with array results with one exception; in tumor tissue with high compared to low COX-2 expression AKT1 expression was significantly higher in PCR analyses, with opposite direction in array analysis.
Table 9

Gene expressions in tumor tissue with high COX-2 expression compared to tumor tissue with low COX-2 expression confirmed by q-PCR

 

CARD 11

TRA@

IL6

IL1B

AKT1

 

High

COX-2 (9)

Low

COX-2 (9)

High

COX-2 (9)

Low

COX-2 (9)

High

COX-2 (9)

Low

COX-2 (9)

High

COX-2 (9)

Low

COX-2 (9)

High

COX-2 (9)

Low

COX-2 (9)

Mean

0.40 ± 0.08

0.42 ± 0.24

2.87 ± 0.63

0.55 ± 0.14

1.97 ± 0.79

0.09 ± 0.03

1.61 ± 0.49

0.27 ± 0.06

1.09 ± 0.13

0.62 ± 0.07

Median

0.39

0.07

3.12

0.44

0.87

0.05

1.01

0.21

0.96

0.59

Variance

0.06

0.50

3.57

0.18

5.65

0.008

2.16

0.04

0.14

0.04

P-value*

ns

0.002

0.03

0.02

0.005

*ANOVA analysis

CARD11 = caspase recruitment domain family, member 11

TRA@ = T cell receptor alpha locus

IL6 = Interleukin 6

IL1B = Interleukin 1β

AKT1 = v-akt murine thymoma viral oncogene homolog 1 or protein kinase B

DNA methylation

A majority of tumor tissue specimens displayed no methylation of the promoter region of the COX-2 gene in tumor tissue; only 2 tumors showed methylation of the promoter region (low COX-2, Dukes B tumors with intermediate differentiation). Methylation of the promoter region of the COX-2 gene was not observed in any of the normal colon mucosa specimens.

Discussion

Increased prostanoid activity is a well recognized characteristic of colorectal cancer [4, 8, 10, 1820]. Early, it was claimed that such tumors have increased COX-2 expression deduced from immunohistochemical evaluations of tumor tissue specimens. More recent investigations have however emphasized that increased COX-2 expression in colorectal cancer is preferentially a local phenomenon with uneven distribution among transformed cells without overall increased tissue content [11]. These findings imply heterogenous cell clones or that other factor are responsible for either up- or down-regulation of COX-2 in malignant cells. It is also important to underline that increased COX-2 expression in tumor tissue may well be confined to stroma and host cells. Such a complex condition supports cross-talk among cells with prostanoids as signals through specific receptors. Our previous investigations have demonstrated a statistically significant relationship between COX-2 expression and tumor tissue production of PGE2, which is elevated in colon cancer tissue [11]. These kinds of findings agree with information that both primary and secondary intervention with cyclooxygenase inhibitors influenced on both local tumor growth and systemic effects in experimental and clinical cancer [4]. Of particular interest may be previous observations that subtype EP2 receptor expression in colon cancer tissue predicted reduced survival [2]. Seen together, it seems that induction of COX-2 is a key-factor behind progression of epithelial cell transformation to invasive cancer in colon mucosa. This logic has been practically explored evaluating the role of COX-2 inhibition on epithelial dysplasia in esophageal mucosa, although without consistent results [21]. However, understanding in part complex cell to cell interactions and signaling in composed tissues it should not be expected to be isolated single factors behind local and systemic tumor progression. Therefore, we intended to evaluate relationships between high COX-2 expression in colon cancer tissue to other factors of known importance for tumor cell division, apoptosis, and metastasis. In this perspective microarray screening should be rewarding.

With this purpose we have quantified COX-2 expression in primary tumors from 48 unselected patients with R0 resected primary tumors. Then, tumor tissue with 10 highest and lowest COX-2 expressions was chosen for subsequent hybridization in various combinations. Such cross-combinations of tissues for microarray expression analyses revealed that tumors with high intrinsic COX-2 expression displayed pronounced up-regulation of genes related to muscle fibers and cytoskeleton matrix, perhaps reflecting matrix remodeling including angiogenesis. By contrast, down-regulated genes in such tumors were more related to functional proteins and eventual cellular antigens (Table 4). Similar findings were observed in comparisons between tumor tissue and normal mucosa from the corresponding patients (Table 3). Most interesting was however, findings that normal colon tissue from patients with high intrinsic COX-2 expression in tumor tissue revealed pronounced up- and down-regulation of several gene functions. Such observations led to the conclusion that colon tissue in patients with colon cancer is significantly altered in regards to functional aspects either primarily or secondary to the appearance of manifest tumor. Analysis of significantly altered pathways at high COX-2 displayed that most alterations were related to immune reactions in the present and previous analyses [22]. This confirms our previous results based on an alternative approach where preoperative COX inhibition by indomethacin mainly affected genes and pathways that involved the immunity [22, 23].

It may be rewarding to understand the control of COX-2 gene expression behind complex in vivo interactions as emphasized. According to this line we evaluated a large number of proposed genes with importance for COX-2 expression as listed in Table 6. Fourteen out of 47 genes were found to have significantly altered expression defined at least as 1.5 fold change compared to normal mucosa or by chance variation in transcript expression. Fos-B/AP1 expression displayed the most pronounced alteration of up-regulated transcripts among transcription factors. A transcription complex known to regulate COX-2 gene expression via binding to CRE-sites in the promoter region is Activator protein 1 (AP-1), which consists of homo- or heterodimers of JUN- and FOS-families with roles in several different cancers. In colorectal cancer AP-1 may be activated by either K-RAS mutation or via Wnt signals. Different genes are transcribed controlling biological activities such as proliferation, apoptosis and differentiation depending on the sub-components of AP-1 [24, 25]. Six of 19 factors with emphasized importance for external cell signaling were up-regulated in tumor tissue of high intrinsic COX-2 expression (Table 7). As expected, such experiments confirmed no significant transcript with decreased expression. IL6 and protein kinas Cβ1 appeared most up-regulated in such cross hybridizations, although transcription of NF-κB was not elevated. In this context it is important to emphasize that protein and gene activation may occur despite evidence of unchanged transcription levels, usually subsequent to phosphorylation changes. Again, it was observed that 9 transcription factors and IL1β, IL6 and iNOS were significantly altered in normal colon tissue from patients with tumors of high intrinsic COX-2 expression. Individual confirmation of array results by PCR determinations displayed also a significantly higher expression of IL1β and IL6 at high COX-2. This phenomenon demonstrates that overall COX-2 expression in primary colorectal carcinoma probably includes primary and secondary alterations in tumor un-involved colon tissue.

It is well recognized that methylation of CpG island located within promoter regions of genes may silence gene expression, described as a hallmark in human cancer. This represents findings early during carcinogenesis and is maintained by DNA methyltransferase (DNMTs) [26]. Such methylation of the COX-2 promoter region may be associated with loss of gene expression as reported for gastric cancer [15, 27]. Similar evidence has been reported for COX-2 gene expression in colorectal cancer [27, 28], although, statistical evaluations of reported observations do not give the impression that COX-2 expression in colon cancer tissue is related to COX-2 promoter methylation. Accordingly, we did not observe significant methylation in two well-defined parts of the COX-2 promoter region in tumor and normal colon tissues. However, DNA methyltransferase was expressed at increased levels in tumor tissue compared to the corresponding normal colon tissue. Therefore, it is unlikely that promoter methylation was a significant factor behind the lack of COX-2 expression in presently investigated areas of colon cancer tissue. It remains to be determined how COX-2 is either induced in tumor tissue with intrinsic high COX-2 expression or down-regulated in tumor cells with correspondingly low overall COX-2 expression to provide the well-recognised scattered pattern of expression observed in immunohistochemical cross tissue sections. Important is our observation that COX-2 expression in normal colon tissue was also significantly increased in patients with tumors of high COX-2 expression. This points to the possibility, that the mucosa or entire colon tissue may be altered as a general phenomenon in patients with certain kind of colon tumors. Perhaps, the inflammatory activation by some kind of bacterial flora(s) could be a speculative guess.

Conclusion

Our present study emphasized and confirmed our previous observations that increased COX-2 expression or tissue content is overall not a unanimous finding in colorectal cancer tissue. A scattered presence of COX-2 may rather represent different cell clones or different local conditions at the cellular level. Both transcription and external cell signaling factors were significantly altered as covariates to COX-2 expression in colon cancer tissue. DNA methylation of the COX-2 promoter region did not seem to be a significant factor behind COX-2 expression in either tumor tissue or normal colon tissue in the present material. Our results confirm that both local and systemic inflammation promote tumor growth and disease progression.

Abbreviations

COX: 

cyclooxygenase

RIN: 

RNA Integrity number.

Declarations

Acknowledgements

Supported in parts by grants from the Swedish Cancer Society (2014), the Swedish Research Council (08712), Assar Gabrielsson Foundation (AB Volvo), Jubileumskliniken Foundation, IngaBritt & Arne Lundberg Research Foundation, Swedish and Gothenburg Medical Societies, the Medical Faculty, University of Gothenburg and Sahlgrenska University Hospital Foundation. We would like to thank the Swegene Gothenburg Genomics resource unit for providing access to the ABI 3730 Sequencer.

Authors’ Affiliations

(1)
Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital
(2)
Department of Clinical Genetics, Institute of Biomedicine, University of Gothenburg

References

  1. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A: The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009, 30 (3): 377-386. 10.1093/carcin/bgp014.View ArticlePubMedGoogle Scholar
  2. Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Wang W, Lonnroth C, Lundholm K: EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer. 2007, 121 (2): 232-240. 10.1002/ijc.22582.View ArticlePubMedGoogle Scholar
  3. Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Lonnroth C, Lundholm K: Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncol. 2007, 1-6.Google Scholar
  4. Cahlin C, Gelin J, Andersson M, Lonnroth C, Lundholm K: The effects of non-selective, preferential-selective and selective COX-inhibitors on the growth of experimental and human tumors in mice related to prostanoid receptors. Int J Oncol. 2005, 27 (4): 913-923.PubMedGoogle Scholar
  5. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW: Aspirin use and risk of fatal cancer. Cancer Res. 1993, 53 (6): 1322-1327.PubMedGoogle Scholar
  6. Muscat JE, Stellman SD, Wynder EL: Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer. 1994, 74 (7): 1847-1854. 10.1002/1097-0142(19941001)74:7<1847::AID-CNCR2820740704>3.0.CO;2-#.View ArticlePubMedGoogle Scholar
  7. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, et al: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003, 348 (10): 883-890. 10.1056/NEJMoa021633.View ArticlePubMedGoogle Scholar
  8. Gelin J, Andersson C, Lundholm K: Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res. 1991, 51 (3): 880-885.PubMedGoogle Scholar
  9. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaninger G, Korner U, Gulich M, Karrefors I, Norli B, et al: Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 1994, 54 (21): 5602-5606.PubMedGoogle Scholar
  10. Hull MA, Ko SC, Hawcroft G: Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer?. Mol Cancer Ther. 2004, 3 (8): 1031-1039.PubMedGoogle Scholar
  11. Cahlin C, Lonnroth C, Arvidsson A, Nordgren S, Lundholm K: Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content. Int J Oncol. 2008, 32 (4): 909-918.PubMedGoogle Scholar
  12. Chun KS, Surh YJ: Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol. 2004, 68 (6): 1089-1100. 10.1016/j.bcp.2004.05.031.View ArticlePubMedGoogle Scholar
  13. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN: Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol. 2006, 38 (10): 1654-1661. 10.1016/j.biocel.2006.03.021.View ArticlePubMedGoogle Scholar
  14. Han W, Cauchi S, Herman JG, Spivack SD: DNA methylation mapping by tag-modified bisulfite genomic sequencing. Anal Biochem. 2006, 355 (1): 50-61. 10.1016/j.ab.2006.05.010.View ArticlePubMedGoogle Scholar
  15. Hur K, Song SH, Lee HS, Ho Kim W, Bang YJ, Yang HK: Aberrant methylation of the specific CpG island portion regulates cyclooxygenase-2 gene expression in human gastric carcinomas. Biochem Biophys Res Commun. 2003, 310 (3): 844-851. 10.1016/j.bbrc.2003.09.095.View ArticlePubMedGoogle Scholar
  16. Tusnady GE, Simon I, Varadi A, Aranyi T: BiSearch: primer-design and search tool for PCR on bisulfite-treated genomes. Nucleic Acids Res. 2005, 33 (1): e9-10.1093/nar/gni012.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T: BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics. 2005, 21 (21): 4067-4068. 10.1093/bioinformatics/bti652.View ArticlePubMedGoogle Scholar
  18. Cao Y, Prescott SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol. 2002, 190 (3): 279-286. 10.1002/jcp.10068.View ArticlePubMedGoogle Scholar
  19. Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, Hagiwara K, Nukiwa T: Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res. 2002, 62 (1): 63-66.PubMedGoogle Scholar
  20. Wang D, Dubois RN: Prostaglandins and cancer. Gut. 2006, 55 (1): 115-122. 10.1136/gut.2004.047100.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Zhi H, Wang L, Zhang J, Zhou C, Ding F, Luo A, Wu M, Zhan Q, Liu Z: Significance of COX-2 expression in human esophageal squamous cell carcinoma. Carcinogenesis. 2006, 27 (6): 1214-1221. 10.1093/carcin/bgi304.View ArticlePubMedGoogle Scholar
  22. Lonnroth C, Andersson M, Arvidsson A, Nordgren S, Brevinge H, Lagerstedt K, Lundholm K: Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun. 2008, 8: 5-PubMedPubMed CentralGoogle Scholar
  23. Gustafsson A, Andersson M, Lagerstedt K, Lonnroth C, Nordgren S, Lundholm K: Receptor and enzyme expression for prostanoid metabolism in colorectal cancer related to tumor tissue PGE2. Int J Oncol. 2010, 36 (2): 469-478.PubMedGoogle Scholar
  24. Ashida R, Tominaga K, Sasaki E, Watanabe T, Fujiwara Y, Oshitani N, Higuchi K, Mitsuyama S, Iwao H, Arakawa T: AP-1 and colorectal cancer. Inflammopharmacology. 2005, 13 (1-3): 113-125. 10.1163/156856005774423935.View ArticlePubMedGoogle Scholar
  25. Grau R, Iniguez MA, Fresno M: Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism. Cancer Res. 2004, 64 (15): 5162-5171. 10.1158/0008-5472.CAN-04-0849.View ArticlePubMedGoogle Scholar
  26. Egger G, Liang G, Aparicio A, Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004, 429 (6990): 457-463. 10.1038/nature02625.View ArticlePubMedGoogle Scholar
  27. Castells A, Paya A, Alenda C, Rodriguez-Moranta F, Agrelo R, Andreu M, Pinol V, Castellvi-Bel S, Jover R, Llor X, et al: Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency. Clin Cancer Res. 2006, 12 (6): 1686-1692. 10.1158/1078-0432.CCR-05-1581.View ArticlePubMedGoogle Scholar
  28. Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa JP: Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res. 2000, 60 (15): 4044-4048.PubMedGoogle Scholar
  29. Kim SP, Park JW, Lee SH, Lim JH, Jang BC, Jang IH, Freund JN, Suh SI, Mun KC, Song DK, et al: Homeodomain protein CDX2 regulates COX-2 expression in colorectal cancer. Biochem Biophys Res Commun. 2004, 315 (1): 93-99. 10.1016/j.bbrc.2004.01.020.View ArticlePubMedGoogle Scholar
  30. Cressey R, Pimpa S, Tontrong W, Watananupong O, Leartprasertsuke N: Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression. Cancer Lett. 2006, 233 (2): 232-239. 10.1016/j.canlet.2005.03.023.View ArticlePubMedGoogle Scholar
  31. Denkert C, Koch I, von Keyserlingk N, Noske A, Niesporek S, Dietel M, Weichert W: Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol. 2006, 19 (9): 1261-1269. 10.1038/modpathol.3800645.View ArticlePubMedGoogle Scholar
  32. Lin DW, Nelson PS: The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma. Clin Prostate Cancer. 2003, 2 (2): 119-126.View ArticlePubMedGoogle Scholar
  33. Duque J, Diaz-Munoz MD, Fresno M, Iniguez MA: Up-regulation of cyclooxygenase-2 by interleukin-1 beta in colon carcinoma cells. Cell Signal. 2006, 18 (8): 1262-1269. 10.1016/j.cellsig.2005.10.009.View ArticlePubMedGoogle Scholar
  34. Maihofner C, Charalambous MP, Bhambra U, Lightfoot T, Geisslinger G, Gooderham NJ: Expression of cyclooxygenase-2 parallels expression of interleukin-1 beta, interleukin-6 and NF-kappaB in human colorectal cancer. Carcinogenesis. 2003, 24 (4): 665-671. 10.1093/carcin/bgg006.View ArticlePubMedGoogle Scholar
  35. Gauthier ML, Pickering CR, Miller CJ, Fordyce CA, Chew KL, Berman HK, Tlsty TD: p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue. Cancer Res. 2005, 65 (5): 1792-1799. 10.1158/0008-5472.CAN-04-3507.View ArticlePubMedGoogle Scholar
  36. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/238/prepub

Copyright

© Asting et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.